What the Study Found (In Plain English)
Published in Human vaccines & immunotherapeutics (2025), this phase iii randomized trial evaluating 340 human participants investigated: Typhoid fever is a significant health concern in low- and middle-income countries, with millions of cases and thousands of deaths each year. Key clinical takeaway: Thus, Typbar TCV® was studied effectively from 6 months to above 85 years, which is the upper age limit. CTRI Registration number: CTRI/2016/01/006476, CTRI/2024/06/069638.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Human vaccines & immunotherapeutics, 2025-12-15; N = 340; Rigor 87/100): Thus, Typbar TCV® was studied effectively from 6 months to above 85 years, which is the upper age limit. CTRI Registration number: CTRI/2016/01/006476, CTRI/2024/06/069638.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.